These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9615120)

  • 41. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 43. [Control of the quality of drug doses in the framework of therapeutic surveillance: Asqualab program 1997-1999].
    Feuillu A; Anglard I; Morel I; Palette C; Marquet P; Roux A; Vassault A
    Ann Biol Clin (Paris); 2000; 58(5):630-6. PubMed ID: 11022111
    [No Abstract]   [Full Text] [Related]  

  • 44. Inpatient compliance of topical applications.
    Hallai N; Finlay AY; Godfrey J; Kamath S; Ahmed Z; Modhazam A
    Br J Dermatol; 2005 Aug; 153(2):446-8. PubMed ID: 16086768
    [No Abstract]   [Full Text] [Related]  

  • 45. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
    Schindler B
    Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
    [No Abstract]   [Full Text] [Related]  

  • 46. [Prescribe topical treatments for psoriasis].
    Lorette G; Fontès V
    Rev Prat; 2004 Jan; 54(1):40-2. PubMed ID: 15049598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization.
    Tanghetti EA; Popp KF
    Dermatol Clin; 2009 Jan; 27(1):17-24. PubMed ID: 18984364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Optimizing topical therapy: results with in vitro models].
    Podhaisky HP; Huschka C; Wohlrab W
    Pharmazie; 1999 Dec; 54(12):871-5. PubMed ID: 10631750
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 50. Topical antipsoriatics.
    Smith KC; Lebwohl M
    Skin Therapy Lett; 2000; 5(2):1-2. PubMed ID: 10751842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prescription reference--drug vehicle system: decisive for effect].
    Wolf G
    Hautarzt; 2007 Dec; 58(12):1008-9. PubMed ID: 18368698
    [No Abstract]   [Full Text] [Related]  

  • 52. Topical calcipotriol is not effective in facial seborrhoeic dermatitis.
    Berth-Jones J; Adnitt PI
    J Dermatolog Treat; 2001 Sep; 12(3):179. PubMed ID: 12243712
    [No Abstract]   [Full Text] [Related]  

  • 53. Instability of topical ciclosporin emulsion for nail psoriasis.
    Prins AM; Vos K; Franssen EJ
    Dermatology; 2007; 215(4):362-3. PubMed ID: 17911999
    [No Abstract]   [Full Text] [Related]  

  • 54. [Topical pharmaceutical forms].
    Zerrouk N; Arnaud P
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S24-6. PubMed ID: 17563710
    [No Abstract]   [Full Text] [Related]  

  • 55. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 56. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [More transparency in drug safety].
    Saussele T
    Med Monatsschr Pharm; 2009 Sep; 32(9):325. PubMed ID: 19795694
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of perioral dermatitis with topical pimecrolimus.
    Rodríguez-Martín M; Sáez-Rodríguez M; Carnerero-Rodríguez A; Rodríguez-García F; Cabrera de Paz R; Sidro-Sarto M; Guimerá F; Sánchez R; García-Bustínduy M; Noda-Cabrera A
    J Am Acad Dermatol; 2007 Mar; 56(3):529-30. PubMed ID: 17317501
    [No Abstract]   [Full Text] [Related]  

  • 59. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 60. [General principles of eczema therapy].
    Harnack K
    Z Arztl Fortbild (Jena); 1990; 84(23):1184-6. PubMed ID: 2085017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.